A clinician's guide to double hit lymphomas
- 22 December 2014
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 168 (6), 784-795
- https://doi.org/10.1111/bjh.13276
Abstract
Double hit lymphomas (DHL) represent a subset of highly aggressive B-cell malignancies characterized by the presence of recurrent cytogenetic rearrangements affecting MYC and either BCL2 and/or BCL6. Recent studies have expanded the concept to include MYC/BCL2 protein co-expressing lymphomas. Around 5-10% of diffuse large B-cell lymphomas are 'double hit' using the cytogenetic definition, whilst around 30-40% are MYC/BCL2 protein co-expressing. In this review, we provide a comprehensive overview of this condition written with the practicing clinician in mind, covering the definition and classification, when DHL should be suspected and how to make the diagnosis, the prognostic factors and a detailed discussion of recent evidence regarding optimal therapy. In particular, we discuss choice of induction regimen, the role of central nervous system-directed prophylaxis, stem cell transplantation and relapsing or refractory disease and provide our opinions based on the currently available evidence. Finally, we highlight some of the more exciting therapies currently in development for this highly aggressive disease.Keywords
This publication has 68 references indexed in Scilit:
- MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapyHaematologica, 2013
- Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell LymphomasPLOS ONE, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell LymphomaThe American Journal of Surgical Pathology, 2010
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survivalBlood, 2009
- Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocationsHaematologica, 2009
- Distinct Thresholds Govern Myc's Biological Output In VivoCancer Cell, 2008
- Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledgeLeukemia, 2008
- Widespread microRNA repression by Myc contributes to tumorigenesisNature Genetics, 2007
- Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomasLeukemia, 2007